The rise of Sildenafil initially fueled a boom for pharma, but recent changes present a complicated scenario for shareholders. Generic versions are eroding profits, and ongoing patent challenges add further complexity https://anyamvkg349069.mybuzzblog.com/21267757/sildenafil-and-pharma-a-precarious-play